Saturday, February 23, 2019 5:59:54 PM
Probably Works; But Is Unworkable
Yes, some really fine therapeutic outcomes. Mental health of Alzheimer's patients wonderfully improved.
But, it was accomplished not with a drug but by an extremely detailed and complicated health "protocol." Simply, the therapists treated just a zillion health problems, and cognition improved.
Would (or could) you administer to Aunt Matilda all of the following when she started for forget stuff?
Here's stuff done and taken:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221920/#!po=34.0909
Optimize diet: minimize simple CHO, minimize inflammation.
Patients given choice of several low glycemic, low inflammatory, low grain diets.
Minimize inflammation, minimize insulin resistance.
Enhance autophagy, ketogenesis
Fast 12 hr each night, including 3 hr prior to bedtime.
Reduce insulin levels, reduce Aß.
Reduce stress; Personalized—yoga or meditation or music, etc.
Reduction of cortisol, CRF, stress axis.
Optimize sleep; 8 hr sleep per night; melatonin 0.5mg po qhs; Trp 500mg po 3x/wk if awakening. Exclude sleep apnea.
Exercise; 30-60' per day, 4-6 days/wk
Brain stimulation
Homocysteine <7
Me-B12, MTHF, P5P; TMG if necessary
[40]
Serum B12 >500
Me-B12
[41]
CRP <1.0; A/G >1.5
Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene
Critical role of inflammation in AD
Fasting insulin <7; HgbA1c <5.5
Diet as above
Type II diabetes-AD relationship
Hormone balance
Optimize fT3, fT4, E2, T, progesterone, pregnenolone, cortisol
[5, 42]
GI health
Repair if needed; prebiotics and probiotics
Avoid inflammation, autoimmunity
Reduction of A-beta
Curcumin, Ashwagandha
43-45
Cognitive enhancement
Bacopa monniera, MgT
[46, 47]
25OH-D3 = 50-100ng/ml
Vitamins D3, K2
[48]
Increase NGF
H. erinaceus or ALCAR
[49, 50]
Provide synaptic structural components
Citicoline, DHA
[51].
Optimize antioxidants
Mixed tocopherols and tocotrienols, Se, blueberries, NAC, ascorbate, a-lipoic acid
[52]
Optimize Zn:fCu ratio
Depends on values obtained
[53]
Ensure nocturnal oxygenation
Exclude or treat sleep apnea
[54]
Optimize mitochondrial function
CoQ or ubiquinol, a-lipoic acid, PQQ, NAC, ALCAR, Se, Zn, resveratrol, ascorbate, thiamine
[55]
Increase focus
Pantothenic acid
Acetylcholine synthesis requirement
Increase SirT1 function
Resveratrol
[32]
Exclude heavy metal toxicity
Evaluate Hg, Pb, Cd; chelate if indicated
CNS effects of heavy metals
MCT effects
Coconut oil or Axona
Yes, some really fine therapeutic outcomes. Mental health of Alzheimer's patients wonderfully improved.
But, it was accomplished not with a drug but by an extremely detailed and complicated health "protocol." Simply, the therapists treated just a zillion health problems, and cognition improved.
Would (or could) you administer to Aunt Matilda all of the following when she started for forget stuff?
Here's stuff done and taken:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221920/#!po=34.0909
Optimize diet: minimize simple CHO, minimize inflammation.
Patients given choice of several low glycemic, low inflammatory, low grain diets.
Minimize inflammation, minimize insulin resistance.
Enhance autophagy, ketogenesis
Fast 12 hr each night, including 3 hr prior to bedtime.
Reduce insulin levels, reduce Aß.
Reduce stress; Personalized—yoga or meditation or music, etc.
Reduction of cortisol, CRF, stress axis.
Optimize sleep; 8 hr sleep per night; melatonin 0.5mg po qhs; Trp 500mg po 3x/wk if awakening. Exclude sleep apnea.
Exercise; 30-60' per day, 4-6 days/wk
Brain stimulation
Homocysteine <7
Me-B12, MTHF, P5P; TMG if necessary
[40]
Serum B12 >500
Me-B12
[41]
CRP <1.0; A/G >1.5
Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene
Critical role of inflammation in AD
Fasting insulin <7; HgbA1c <5.5
Diet as above
Type II diabetes-AD relationship
Hormone balance
Optimize fT3, fT4, E2, T, progesterone, pregnenolone, cortisol
[5, 42]
GI health
Repair if needed; prebiotics and probiotics
Avoid inflammation, autoimmunity
Reduction of A-beta
Curcumin, Ashwagandha
43-45
Cognitive enhancement
Bacopa monniera, MgT
[46, 47]
25OH-D3 = 50-100ng/ml
Vitamins D3, K2
[48]
Increase NGF
H. erinaceus or ALCAR
[49, 50]
Provide synaptic structural components
Citicoline, DHA
[51].
Optimize antioxidants
Mixed tocopherols and tocotrienols, Se, blueberries, NAC, ascorbate, a-lipoic acid
[52]
Optimize Zn:fCu ratio
Depends on values obtained
[53]
Ensure nocturnal oxygenation
Exclude or treat sleep apnea
[54]
Optimize mitochondrial function
CoQ or ubiquinol, a-lipoic acid, PQQ, NAC, ALCAR, Se, Zn, resveratrol, ascorbate, thiamine
[55]
Increase focus
Pantothenic acid
Acetylcholine synthesis requirement
Increase SirT1 function
Resveratrol
[32]
Exclude heavy metal toxicity
Evaluate Hg, Pb, Cd; chelate if indicated
CNS effects of heavy metals
MCT effects
Coconut oil or Axona
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
